Interne link ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration december 11, 2024 om 12:00 PM UTC
Interne link ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist december 10, 2024 om 01:00 PM UTC
Interne link ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 december 05, 2024 om 01:00 PM UTC
Interne link ProQR Announces Third Quarter 2024 Operating and Financial Results november 07, 2024 om 12:00 PM UTC
Interne link ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement oktober 25, 2024 om 08:45 PM UTC
Interne link ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement oktober 23, 2024 om 02:15 AM UTC
Interne link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares oktober 22, 2024 om 08:01 PM UTC
Interne link ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society oktober 07, 2024 om 12:00 PM UTC
Interne link ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference september 10, 2024 om 08:30 PM UTC
Interne link ProQR Announces Second Quarter 2024 Operating and Financial Results augustus 08, 2024 om 11:00 AM UTC
Interne link ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit juni 18, 2024 om 12:00 PM UTC
Interne link ProQR Announces First Quarter 2024 Operating and Financial Results mei 09, 2024 om 11:00 AM UTC
Interne link ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases mei 08, 2024 om 12:00 PM UTC
Interne link ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024 april 23, 2024 om 11:00 AM UTC
Interne link ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting april 22, 2024 om 08:31 PM UTC
Interne link ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio april 19, 2024 om 11:00 AM UTC
Interne link ProQR Announces Year End 2023 Operating and Financial Results maart 13, 2024 om 11:00 AM UTC
Interne link ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing februari 15, 2024 om 12:00 PM UTC
Interne link ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 januari 19, 2024 om 12:00 PM UTC
Interne link ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration januari 05, 2024 om 12:00 PM UTC
Interne link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets december 08, 2023 om 12:30 PM UTC
Interne link ProQR Announces Third Quarter 2023 Operating and Financial Results november 07, 2023 om 12:00 PM UTC
Interne link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing november 06, 2023 om 12:00 PM UTC
Interne link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference september 28, 2023 om 12:00 PM UTC
Interne link ProQR Therapeutics Provides Update on Ophthalmic Assets september 27, 2023 om 11:00 AM UTC